Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL), Neurocrine (NBIX) and Inmune Bio (INMB) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cardiol Therapeutics (CRDL)
Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Cardiol Therapeutics on April 6 and set a price target of $8.00. The company’s shares closed last Tuesday at $1.40.
According to TipRanks.com, Nash is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardiol Therapeutics with a $8.50 average price target, implying a 525.0% upside from current levels. In a report issued on April 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
See today’s best-performing stocks on TipRanks >>
Neurocrine (NBIX)
In a report issued on April 6, Ashwani Verma from UBS maintained a Buy rating on Neurocrine, with a price target of $161.00. The company’s shares closed last Tuesday at $130.90.
According to TipRanks.com, Verma is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $183.10 average price target, representing a 37.3% upside. In a report issued on April 6, Needham also maintained a Buy rating on the stock with a $185.00 price target.
Inmune Bio (INMB)
Alliance Global Partners analyst James Molloy maintained a Buy rating on Inmune Bio on April 6 and set a price target of $7.00. The company’s shares closed last Tuesday at $1.27.
According to TipRanks.com, Molloy is ranked 0 out of 5 stars with an average return of
Inmune Bio has an analyst consensus of Strong Buy, with a price target consensus of $8.00, a 540.0% upside from current levels. In a report issued on March 31, Maxim Group also maintained a Buy rating on the stock with a $8.00 price target.
Read More on CRDL:
Disclaimer & DisclosureReport an Issue
- Cardiol Therapeutics Details 2025 Progress and Funding for Late-Stage Cardiac Drug Programs
- CRDL Upcoming Earnings Report: What to Expect?
- Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference
- Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure
